Education
About Us
Working with TipRanks
Follow Us
2cureX AB (SE:2CUREX)
:2CUREX
Top Page
2cureX AB
(2CUREX)
Select Model
Select Model
Rating:50Neutral
Price Target:
kr1.50
▲(177.78% Upside)
The score is primarily held back by weak financial quality—persistent losses, near-zero revenue, and ongoing negative free cash flow despite improvement in 2024. Technicals are mixed (short-term strength but longer-term downtrend with negative MACD), while valuation gets modest support from the high dividend yield but is constrained by negative earnings.
2cureX AB (2CUREX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr14.31M
Dividend Yield11.26%
Average Volume (3M)53.14K
Price to Earnings (P/E)―
Beta (1Y)0.42
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding25,102,917
10 Day Avg. Volume69,592
30 Day Avg. Volume53,143
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
2cureX AB Business Overview & Revenue Model
Company Description2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic cancers. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.
How the Company Makes Money
2cureX AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.18M | 0.00 | 155.00K | 90.00K | 7.39M | 15.39M |
| Gross Profit | -12.53M | 0.00 | -9.27M | -9.02M | 7.04M | 15.01M |
| EBITDA | -28.18M | -4.13M | -35.14M | -29.46M | -22.13M | -8.21M |
| Net Income | -24.65M | -4.13M | -32.52M | -29.77M | -18.94M | -7.32M |
Balance Sheet | ||||||
| Total Assets | 7.05M | 7.75M | 16.28M | 47.66M | 79.16M | 63.04M |
| Cash, Cash Equivalents and Short-Term Investments | 3.13M | 5.14M | 13.40M | 44.89M | 72.94M | 58.58M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.26M | 2.65M | 4.20M | 4.62M | 4.82M | 4.18M |
| Stockholders Equity | 2.79M | 5.10M | 12.08M | 43.03M | 74.34M | 58.86M |
Cash Flow | ||||||
| Free Cash Flow | -22.61M | -4.63M | -31.24M | -28.52M | -18.46M | -12.10M |
| Operating Cash Flow | -22.59M | -4.63M | -31.22M | -27.98M | -18.43M | -11.69M |
| Investing Cash Flow | -6.00K | 5.62M | -17.00K | -541.00K | -32.00K | -403.00K |
| Financing Cash Flow | 0.00 | 2.69M | 0.00 | 0.00 | 32.55M | 37.61M |
2cureX AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:2CUREX
2cureX AB
1.40
1.00
247.39%
DE:8LY
OncoZenge AB
0.54
0.20
58.41%
DE:5LD
LIDDS AB
0.01
0.00
0.00%
DE:5JD0
ExpreS2ion Biotech Holding AB
1.48
-0.47
-23.90%
DE:COJ0
CombiGene AB
0.17
0.01
8.44%
DE:5JA1
Sprint Bioscience AB
0.13
<0.01
8.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.